Tango Therapeutics
Open
$21.85
Prev. Close
$21.87
High
$21.98
Low
$21.85
Market Snapshot
$2.97B
-29.2
-1.20
$42.07M
137
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The company is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. The company is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
emptyResult
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2020-09-03. The firm's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The company is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. The company is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
Recently from Cashu
Tango Therapeutics Enhances Talent Acquisition with New Equity Awards for Employees
Tango Therapeutics Strengthens Talent Acquisition Strategy with New Equity Awards Tango Therapeutics, Inc., a clinical-stage biotechnology company dedicated to precision cancer medicine, announces the…
Tango Therapeutics to Present Innovative Cancer Research at Upcoming Healthcare Conference
Tango Therapeutics to Showcase Innovative Cancer Research at Upcoming Conference Tango Therapeutics, Inc., a pioneering player in the development of precision cancer medicines, prepares to highlight i…
Tango Therapeutics Reports Promising Results for TNG462 in Cancer Treatment Advancements
Tango Therapeutics Advances PRMT5 Program with Promising Clinical Results Tango Therapeutics, Inc., a clinical-stage biotechnology company specializing in precision cancer therapies, announces signifi…